Trovagene to sell underwritten public offering of common stock

Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Friday, February 6, 2015.

Piper Jaffray & Co. is acting as sole book-running manager for the offering.

A registration statement relating to the shares described above was previously filed with and has become effective by rule of the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and the related prospectus will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

SOURCE Trovagene, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New therapeutic approach prevents growth of metastatic tumors by putting cancer cells to sleep